# SYBX catalysts: SYNLOGIC, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sybx/catalysts

> SYNLOGIC, INC. (SYBX) has no upcoming catalysts in this calendar. The latest recorded is the SYNLOGIC, INC. earnings report, November 12, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | SYNLOGIC, INC. |
| Ticker | SYBX (OTC) |
| SEC CIK | 1527599 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sybx |

## Cash runway

Cash $11.6M as of 2026-09-30; quarterly burn $1.6M; about 21.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-455905).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2022 | [Labafenogene topline data readout](https://sec-api.dev/pdufa/labafenogene) | SYBX |  | completed, positive | "In October 2022, we shared positive top-line results from the Phase 2 Synpheny-1 study that demonstrated proof of concept in PKU patients for both candidates, and confirmed greater potency of the next-generation labafenogene marselecobac , the candidate that we have selected to advance to pivotal Phase 3 studies." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1527599/000095017025034820/sybx-20241231.htm)) |
| November 12, 2024 | [SYNLOGIC, INC. earnings report](https://sec-api.dev/companies/sybx/catalysts) | SYBX |  | completed | "Synlogic Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/sybx-ex99_1.htm)) |

## Drugs

- [Labafenogene](https://sec-api.dev/pdufa/labafenogene): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sybx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SYBX catalysts: SYNLOGIC, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sybx/catalysts

```bibtex
@misc{secapidev_companies_sybx_catalysts_20261116,
  title        = {SYBX catalysts: SYNLOGIC, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sybx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sybx_catalysts_20261116","title":"SYBX catalysts: SYNLOGIC, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sybx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
